The UK government has added 82 items to its list of medicines that cannot be parallel exported from the country. Among the items that cannot be parallel exported from the UK as of 21 March are amoxicillin, paracetamol and insulin, as well as enoxaparin, heparin, hydrocortisone, morphine, ondansetron and proton pump inhibitors such as lansoprazole, omeprazole, and pantoprazole.
UK Blocks 82 From Parallel Export
BGMA Does Not Foresee Imminent Shortages Amid Coronavirus
The UK government has added 82 items to its list of medicines that cannot be parallel exported from the country, including amoxicillin, insulin, paracetamol and several common proton pump inhibitors. The move comes as local off-patent industry association the BGMA has insisted that no short-term or medium-term shortages are foreseen amid the coronavirus pandemic.
More from Regulation
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
The EMA has accepted for review Henlius’ Perjeta biosimilar, which is to be commercialized by the Chinese company’s global partner Organon in the EU.
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
More from Policy & Regulation
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
Echoing wider sentiments in the biosimilar and generic drug industry, the IGBA has warned of the potential consequences of mercantilist tariffs on the global drug supply and their impact on industry and patients.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).